Ann: Trading Halt, page-75

First 75 Last

Share
Profile

Follow
Gekkowolf

2,403 Posts.

241

22/11/17

17:53

Post #: 29030888
Share

Originally posted by amcfutures ↑

Although I reserve my final judgment until I’ve seen details of the BP agreement… presumably tomorrow
Questions that come to mind include…
Is the placement fully underwritten by BP?
Do BP have an options to buy any shares that are not taken up?
Is IMU banned from making any announcements that might affect the price and, if so, for what period?
If so, and I think such is standard practice, we are fully reliant on BP to make the case to investors?

At this stage I have to say I’m disappointed with the outcome. While I was expecting either institutional or big pharma injection I was very much hoping it would be the latter.

Why? Because I don’t see this move as an endorsement of the technology as such but rather as one in which the management team did a great job is selling the story of potential to prospective investors and then to BP…. Cynically one might say they write mighty good sales-copy.

The bottom-line as I see is that all we are attracting are what I call ‘passive’ investors. ‘Passive’ investors other than supplying the capital (while it suits them to do so) add no momentum to the company.

In contrast, a Big Pharma partner comes on-board not only because they endorse the technology but because they know how to make things happen and have the backup resources to move mountains.

Ever wondered why, for example, 75% of the FDA budget comes from Big Pharma… how about favorable trial design and directing staff resources to expedite assessment for starters.

To my mind we are now stuck with a comparatively ‘mickey-mouse’ arrangement under which if progress with the trial to date is anything to go by will drag on for years.

I really, truly hope all I’ve written is just a nightmare and when I wake up the sun will be shining and my piggy-bank overflowing!

Expand

I don’t think Big Pharma will be interested in any deal until the results are definitive. What concerns me is this could be some considerable time off. And how many more cap raisings will there be????

DYOR!!!!

IMU Price at posting: 2.3¢ Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 32 more messages in this thread...

First 75 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change -0.002(4.00%)		Mkt cap ! $353.2M

Open	High	Low	Value	Volume
5.0¢	5.0¢	4.7¢	$1.758M	36.63M

Buyers (Bids)

No.	Vol.	Price($)
12	845485	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	7114378	20

View Market Depth

No.	Vol.	Price($)
12	846046	0.048
46	7338300	0.047
52	5392825	0.046
56	8537909	0.045
18	3296870	0.044

Price($)	Vol.	No.
0.049	7114278	19
0.050	3032157	18
0.051	6373880	12
0.052	2033350	7
0.053	896882	8

Last trade - 14.21pm 27/09/2024 (20 minute delay)

IMU (ASX) Chart

Ann: Trading Halt, page-75

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Trading Halt, page-75

Top Stories

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News